Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 4;10:1779. doi: 10.1038/s41598-020-58072-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

AAV-miRzip-21 effectively reduces cancer cell progression in vivo (A) Illustration showing the proposed hypothesis of MSC based delivery of anti-miR-21 to tumor cells. (B) RT-PCR assay showing miR-21 expression in LV-miRzip-21 transduced-MSCs and exosomes extracted from transduced MSC. Negative and RT-minus controls are indicated by NT and -RT, respectively. UT and SC represent untreated and scramble control groups, respectively. (C) Plots and representative fluorescent micrographs of cancer cells cocultured with LV-miRzip-21 expressing MSCs at 3:1 ratio showing cell viability at 120 h. Scale bars: 100 uM (D) Plots and representative fluorescent micrographs of cancer cells cocultured with LV-miRzip-21 infected-MSCs at 1:1 ratio and corresponding cell viability at 120 h. Scale bars: 50 uM (E) Illustration showing the model for AAV transduction of tumor cells (F) Plot showing changes in tumor cell viability at 72 h post transduction with AAV-miRzip-21 and control. (G) Illustration of the in vivo subcutaneous model of colon and prostate cancers. (H) Plot showing changes in bioluminescence signal intensity overtime following AAV-miRzip-21 injection. (I) Illustration of the intracranial LN229-FmC animal model. (J) Plot showing changes in bioluminescence signal intensity overtime following AAV injection. Data presented as mean ± SD. ***(P < 0.01) and *(P < 0.5).